|
Patient-related factor
|
|
Age (per 1 year)
|
1.01 (1.00–1.02)
|
0.005
|
1.02 (1.01–1.03)
|
0.003
|
|
Sex (Male vs. Female)
|
1.02 (0.80–1.30)
|
0.889
| | |
|
KPS
|
|
(80 vs. ≤70)
|
1.06 (0.79–1.42)
|
0.697
| | |
|
(≥90 vs. ≤70)
|
0.78 (0.58–1.06)
|
0.112
| | |
|
Baseline TLC (< 1000/μL vs. ≥1000/μL)
|
1.25 (0.94–1.64)
|
0.119
| | |
|
Tumor-related factor
|
|
Extent of resection
|
|
(Subtotal/Partial vs. Total)
|
1.78 (1.38–2.31)
|
<.001
|
1.75 (1.33–2.31)
|
<.001
|
|
(Biopsy vs. Total)
|
1.69 (1.06–2.70)
|
0.028
|
1.50 (0.93–2.43)
|
0.095
|
|
IDH1 mutation
|
|
(Yes vs. No)
|
0.25 (0.11–0.55)
|
<.001
|
0.30 (0.13–0.69)
|
0.005
|
|
(Unknown vs. No)
|
1.14 (0.86–1.52)
|
0.360
|
0.97 (0.71–1.31)
|
0.818
|
|
MGMT (Methylated vs. Unmethylated)
|
0.46 (0.35–0.60)
|
<.001
|
0.48 (0.37–0.63)
|
<.001
|
|
Subventriclular zone (Involved vs. Uninvolved)
|
1.57 (1.23–2.01)
|
<.001
|
1.52 (1.17–1.96)
|
0.001
|
|
Treatment-related factor
|
|
The cumulative dose of temozolomide (per 100 mg/m2)
|
1.00 (0.99–1.00)
|
0.260
|
1.00 (0.99–1.01)
|
0.597
|
|
PTV1 volume (per 10 cm3)
|
1.01 (1.00–1.01)
|
0.132
| | |
|
PTV2 volume (per 10 cm3)
|
1.02 (1.00–1.03)
|
0.029
|
1.01 (0.99–1.02)
|
0.305
|
|
Radiotherapy modality (IMRT vs. 3D-CRT)
|
0.91 (0.71–1.17)
|
0.483
| | |
|
Total dose (per 1 Gy)
|
0.98 (0.95–1.01)
|
0.187
| | |
|
No. of fractionation (per 1)
|
0.99 (0.94–1.05)
|
0.845
| | |
|
Acute severe lymphopenia (Yes vs. No)
|
1.32 (1.03–1.69)
|
0.028
|
1.04 (0.81–1.35)
|
0.756
|
